JasonEdwardFarisMD

Oncology • Lebanon, NH

Gastrointestinal Cancer, Hematologic Oncology

Director of Early Phase Clinical Trials; Assistant Professor, Geisel School of Medicine

Join to view full profile

Dr. Faris is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Faris' full profile

Already have an account?

Office
Dartmouth-Hitchcock Medical Center
Lebanon, NH 03756

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2008 - 2011
Massachusetts General HospitalChief Residency, Internal Medicine, 2010 - 2010
Massachusetts General HospitalResidency, Internal Medicine, 2005 - 2008
Johns Hopkins University School of MedicineClass of 2005

Certifications & Licensure

NH State Medical License 2019 - 2025
MA State Medical License 2007 - 2020
American Board of Internal Medicine Medical Oncology

Clinical Trials

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Start of enrollment: 2012 Jul 01
Completed
Phase 2
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer Start of enrollment: 2012 Nov 23
Completed
Phase 2
A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer Start of enrollment: 2014 Jan 01
Withdrawn
Phase 1, Phase 2
Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies Start of enrollment: 2020 Sep 22
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

12 citations
Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
Emilie A Chapeau, Laurent Sansregret, Giorgio G Galli, Patrick Chène, Markus Wartmann
Nature Cancer. 2024-07-01
2 citations
Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
Emilie A Chapeau, Laurent Sansregret, Giorgio G Galli, Patrick Chène, Markus Wartmann
Nature Cancer. 2024-07-01
9 citations
A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events.
Patrick Schöffski, Nicole Concin, Cristina Suarez, Vivek Subbiah, Yuichi Ando
Oncology Research and Treatment. 2021-10-01

Committees

Editorial Board Member, National Cancer Institute Adult Treatment Editorial Board 2012 - 2015

Professional Memberships